Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group

Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines

Go back to Resources

Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

ABO - mismatched renal transplantation (RT) in children: A report of the N Am Renal Transpl Co-op Study,

Go back to Resources

ABO - mismatched renal transplantation (RT) in children: A report of the N Am Renal Transpl Co-op Study,

Authors:

Location:

Go back to Resources

A partially grouped logrank test and modifications for sequential monitoring.

Go back to Resources

A partially grouped logrank test and modifications for sequential monitoring.

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Vinorelbine Tartrate [in the treatment of breast cancer],

Go back to Resources

Vinorelbine Tartrate [in the treatment of breast cancer],

Authors:

Secondary:

Pagination:

Go back to Resources

Varicella requiring hospitalization in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS),

Go back to Resources

Varicella requiring hospitalization in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS),

Authors:

Location:

Go back to Resources

Varicella in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study.

Go back to Resources

Varicella in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study.

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Validity of JVA interpretation in conjunction with RDC history & clinical examination to assess TMD,

Go back to Resources

Validity of JVA interpretation in conjunction with RDC history & clinical examination to assess TMD,

Authors:

Location:

Go back to Resources

Trial of calcium for preeclampsia prevention (CPEP): rationale, design and methods,

Go back to Resources

Trial of calcium for preeclampsia prevention (CPEP): rationale, design and methods,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute; 5-year follow-up report,

Go back to Resources

Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute; 5-year follow-up report,

Authors:

Secondary:

Volume:

Go back to Resources

The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).

Go back to Resources

The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).

Authors:

Secondary:

Pagination:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 127
  • Page 128
  • Page 129
  • Page 130
  • Current page 131
  • Page 132
  • Page 133
  • Page 134
  • Page 135
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification